表紙
市場調查報告書

生物相似藥的各種聯盟契約:契約條件、協定內容

Global Biosimilars Partnering Terms and Agreements 2014 to 2019

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 712891
出版日期 內容資訊 英文 90+ Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物相似藥的各種聯盟契約:契約條件、協定內容 Global Biosimilars Partnering Terms and Agreements 2014 to 2019
出版日期: 2019年06月01日內容資訊: 英文 90+ Pages
簡介

本報告提供生物相似藥相關的近幾年的各種聯盟契約的相關調查,進行近幾年的趨勢、趨勢,活躍地聯盟契約的企業,主要的大規模契約,各種聯盟契約的交易額、契約類型、技術區分、協定內容、目的、條件等的各種資料彙整。

摘要整理

第1章 簡介

第2章 生物相似藥的各種契約動向

  • 簡介
  • 過去數年的聯盟趨勢
  • 聯盟最活躍的經營者
  • 聯盟契約動向:各類型契約
  • 聯盟契約動向:各治療領域
  • 聯盟契約動向:各產品部門
  • 契約內容
    • 交易總額
    • 預付款金
    • 里程碑
    • 權利金費率
  • 生物相似藥契約結構
    • 案例研究:RRD International、Dipexium Pharmaceuticals
    • 案例研究:Hospira、Cempra Pharmaceutical
    • 案例研究:Astellas Pharma Inc.、Optimer Pharmaceuticals

第3章 主要契約

  • 簡介
  • 大型契約:各契約金額

第4章 聯盟最活躍的經營者

  • 簡介
  • 聯盟最活躍的經營者
  • 聯盟最活躍的經營者:企業簡介

第5章 生物相似藥的契約目錄

第6章 生物相似藥的契約動向:各技術類型

  • 生物相似藥
  • Aminoglycosides
  • 頭孢菌素
  • 克林達黴素
  • 大環內酯類
  • 甲硝唑
  • 青霉素
  • 奎諾酮類抗生素(Quinolones)
  • 四環黴素

第7章 聯盟資源中心

  • 線上聯盟
  • 聯盟活動
  • 相關報告

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2124

‘The Global Biosimilars Partnering Terms and Agreements 2014 to 2019 report ’ provides comprehensive understanding and unprecedented access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Biosimilars Partnering Terms and Agreements 2014 to 2019 report ’ provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Biosimilars partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Biosimilars partnering contract documents
  • Top Biosimilars deals by value

‘The Global Biosimilars Partnering Terms and Agreements report ’ provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biosimilars deals since 2014. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope

‘Global Biosimilars Partnering Terms and Agreements 2014 to 2019’ is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

‘Global Biosimilars Partnering Terms and Agreements 2014 to 2019’ includes:

  • Trends in Biosimilars dealmaking in the biopharma industry since 2014
  • Analysis of Biosimilars deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Biosimilars deals
  • Access to over 70 Biosimilars deal records and contract documents where available
  • The leading Biosimilar deals by value since 2014
  • Most active Biosimilars dealmakers since 2014
  • The leading Biosimilars partnering resources

In ‘Global Biosimilars Partnering Terms and Agreements 2014 to 2019’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

‘Global Biosimilars Partnering Terms and Agreements 2014 to 2019 ’ provides the reader with the following key benefits:

  • In-depth understanding of Biosimilars deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biosimilars agreements with numerous real life case studies
  • Comprehensive access to Biosimilars deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Biosimilars deals by value since 2014
  • Identify the most active Biosimilars dealmakers since 2014
  • Detailed access to actual Biosimilars contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Biosimilars agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biosimilars dealmaking

  • 2.1. Introduction
  • 2.2. Biosimilars partnering over the years
  • 2.3. Most active Biosimilars dealmakers
  • 2.4. Biosimilars partnering by deal type
  • 2.5. Biosimilars partnering by therapy area
  • 2.6. Biosimilars partnering by industry sector
  • 2.7. Deal terms for Biosimilars partnering
    • 2.7.1 Biosimilars partnering headline values
    • 2.7.2 Biosimilars deal upfront payments
    • 2.7.3 Biosimilars deal milestone payments
    • 2.7.4 Biosimilars royalty rates
  • 2.8. The anatomy of an Biosimilars deal
  • 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
  • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
  • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Biosimilars deals

  • 3.1. Introduction
  • 3.2. Top Biosimilars deals by value

Chapter 4 - Most active Biosimilars dealmakers

  • 4.1. Introduction
  • 4.2. Most active Biosimilars dealmakers
  • 4.3. Most active Biosimilars partnering company profiles

Chapter 5 - Biosimilars contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Biosimilars contracts dealmaking directory

Chapter 6 - Biosimilars dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Biosimilars deals by company A-Z
  • Appendix 2 - Biosimilars deals by stage of development
  • Appendix 3 - Biosimilars deals by deal type
  • Appendix 4 - Biosimilars deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Biosimilars partnering since 2014
  • Figure 2: Active Biosimilars dealmaking activity sincce 2014
  • Figure 3: Biosimilars partnering by deal type since 2014
  • Figure 4: Biosimilars partnering by disease type since 2014
  • Figure 5: Biosimilars partnering by industry sector since 2014
  • Figure 6: Biosimilars deals with a headline value
  • Figure 7: Biosimilars deals with an upfront value
  • Figure 8: Biosimilars deals with a milestone value
  • Figure 9: Biosimilars deals with a royalty rate value
  • Figure 10: Top Biosimilars deals by value since 2014
  • Figure 11: Most active Biosimilars dealmakers since 2014
  • Figure 12: Biosimilars partnering by technology type since 2014
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top